Subsequent Event |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Subsequent Events [Abstract] | |
| Subsequent Event |
18. Subsequent Event Third-party clinical trial supply organization In July 2025, the Company entered into a clinical trial supply agreement in the amount of approximately $6.5 million with a clinical trial supply organization whereby the clinical trial supply organization will provide services for the Company's forthcoming PAH Phase 2b clinical study, known as IMPROVE-PAH. Third-party clinical research organization On August 8, 2025, the Company entered into an arrangement with a contract research organization to support the Company's forthcoming PAH Phase 2b clinical study known as IMPROVE-PAH in the amount of approximately $22.3 million. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|